<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Acquir Immune Defic Syndr</journal-id><journal-id journal-id-type="iso-abbrev">J. Acquir. Immune Defic. Syndr</journal-id><journal-id journal-id-type="publisher-id">qai</journal-id><journal-title-group><journal-title>Journal of Acquired Immune Deficiency Syndromes (1999)</journal-title></journal-title-group><issn pub-type="ppub">1525-4135</issn><issn pub-type="epub">1944-7884</issn><publisher><publisher-name>JAIDS Journal of Acquired Immune Deficiency Syndromes</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4819527</article-id><article-id pub-id-type="publisher-id">QAIV16389</article-id><article-id pub-id-type="doi">10.1097/QAI.0000000000000916</article-id><article-id pub-id-type="art-access-id">00021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial: Erratum</article-title></title-group><pub-date pub-type="ppub"><day>1</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2015</year></pub-date><volume>71</volume><issue>1</issue><fpage>e33</fpage><lpage>e33</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri xlink:type="simple" xlink:href="qai-71-e33.pdf"/><custom-meta-group><custom-meta><meta-name>STATUS</meta-name><meta-value>ONLINE-ONLY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>In the article by Walmsley et al, appearing in the <italic>Journal of Acquired Immune Deficiency Syndromes</italic>, Vol. 70, No. 5, pp. 515&#x02013;519, entitled &#x0201c;Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial,&#x0201d; there is an error in the abstract text regarding the incidence of discontinuations due to adverse events through week 144. The sentence should read, &#x0201c;Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 16 (4%); efavirenz/tenofovir/emtricitabine arm, 58 (14%)] through W144.&#x0201d; The data in the body of the manuscript are correct.</p></body><back><ref-list><title>REFERENCE</title><ref id="R1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walmsley</surname><given-names>S</given-names></name><name><surname>Baumgarten</surname><given-names>A</given-names></name><name><surname>Berenguer</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-na&#x000ef;ve patients: week 96 and week 144 results from the SINGLE randomized clinical trial</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>;<volume>70</volume>:<fpage>515</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">26262777</pub-id></mixed-citation></ref></ref-list></back></article>